U.S. FTC settles with Vyera over Daraprim, Shkreli trial still on
Reuters
Published Dec 07, 2021 02:25PM ET
Updated Dec 07, 2021 04:46PM ET
By Diane Bartz and Jonathan Stempel
WASHINGTON (Reuters) - The U.S. Federal Trade Commission and seven states on Tuesday settled claims accusing Vyera Pharmaceuticals of trying to block generic versions of its life-saving drug Daraprim, but are preparing for a Dec. 14 trial against accused mastermind Martin Shkreli.
Tuesday's settlement, worth up to $40 million, addressed claims in a Jan. 2020 lawsuit that Shkreli and co-defendant Kevin Mulleady launched Vyera with a goal of buying an important drug, raising the price, and using illegal anticompetitive strategies to thwart cheaper generics.
Vyera, then Turing Pharmaceuticals, allegedly protected its dominance of Daraprim by ensuring that generic drugmakers could not obtain samples for cheaper versions, and kept potential rivals from buying a key ingredient.
Shkreli gained notoriety in 2015 when he boosted the price of Daraprim overnight to $750 from $17.50 per tablet.
Daraprim is used to treat toxoplasmosis, a common parasitic infection that threatens people with weakened immune systems.
The settlement calls for Vyera to pay $10 million upfront plus up to $30 million over 10 years, and halt anticompetitive practices.
Mulleady, who like Shkreli was also a Vyera chief executive, agreed to a seven-year ban from most roles in the pharmaceutical industry.
U.S. District Judge Denise Cote in Manhattan approved the accord. She would oversee Shkreli's trial.
Mulleady's lawyer Marc Kasowitz said his client "vehemently" denied the claims against him, but believed the resolution was best for him and the companies.
Vyera, its lawyers and Shkreli's lawyers did not immediately respond to requests for comment.
Shkreli is serving a seven-year prison term after his 2017 conviction for cheating investors in two hedge funds and trying to prop up the stock price of another drug company he led, Retrophin (NASDAQ:TVTX) Inc. He is eligible for release in October 2022.
New York Attorney General Letitia James, whose state co-led the lawsuit, welcomed the proposed settlement.
Alluding to a common nickname for Shkreli, James said the defendants "shamelessly engaged in illegal conduct that allowed them to maintain their exorbitant and monopolistic price of a life-saving drug -- letting Pharma Bros get rich, while others paid the price."
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.